Details of the Drug

General Information of Drug (ID: DMMRANJ)

Drug Name
Anti-CD19-CAR T
Indication
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Phase 1 [1]
Lymphoma 2A80-2A86 Phase 1 [1]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D03EIA
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease leukaemia
ICD Disease Classification 2A60-2B33
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL